Insights into Doublet Therapy and Clinical Trial Takeaways for Metastatic Prostate Cancer Treatment : Episode 8
Opinion
Video
The Evolving Role of Radium-223 in mCRPC and the Impact of Combination Therapies
Author(s):
Key Takeaways
- The PEACE III study explores combining radium-223 with androgen receptor-targeted therapies to improve PSA control in prostate cancer treatment.
- Radium-223's poor clinical uptake is due to its inability to control PSA alone, necessitating combination with androgen receptor inhibitors.
Panelists discuss how combining radium-223 with androgen receptor–targeted therapy like enzalutamide addresses historical challenges in treating metastatic castration-resistant prostate cancer, including poor radium-223 uptake, prostate-specific androgen–level control issues, and the need for multimodal treatment approaches.
Video Player is loading.
Video Content above is prompted by the following:
- What are the challenges, historically, that the PEACE III study addresses?
- Discuss reasons for the relatively poor uptake of radium-223 (Xofigo) in the clinic.
- Radium alone doesn’t control prostate-specific androgen (PSA), nor does docetaxel. PSA control is addressed by androgen receptor inhibitor (ARI).
- Layered radium-223 and enzalutamide plus ARI will control PSA, so radium-223 can be administered without being questioned or second-guessed.
- Similar to the ARASENS trial, maintain relationship and management and share care with med oncology for docetaxel.
- Discuss the rationale for combining radium-223 with androgen receptor–targeted therapy (enzalutamide). (Sartor et al [2018]; Shore et al [2020])
- Allows for 2 distinct mechanisms of action.
Related Videos
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Checkpoint Inhibitors for Treatment of NMIBC
Communication of Treatment Options for High-Risk NMIBC
Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
BPH: The Patient Journey
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
Addressing Remaining Unmet Needs in mCRPC
Use and Sequencing of Novel Treatments in NMIBC
The DORA Trial
Related Content
